about
Chronic thromboembolic pulmonary hypertensionEfficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort studyThe Italian START-Register on Anticoagulation with Focus on Atrial FibrillationDescriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).Argatroban in the management of heparin-induced thrombocytopenia.Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study.Dyspnoea in a young woman: the opposite of every truth is just as true.Risks factors for highly unstable response to oral anticoagulation: a case-control study.The redox enzyme p66Shc contributes to diabetes and ischemia-induced delay in cutaneous wound healing.Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.Interpretation of laboratory data and need for reference laboratories.Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism.D-dimer testing to determine the duration of anticoagulation therapy.Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs.New trends in anticoagulant treatments.Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature.Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysisRecovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature.Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention.APS--controversies in diagnosis and management, critical overview of current guidelines.Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment.Management of special conditions in patients on vitamin K antagonists.What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?Correct laboratory approach to APS diagnosis and monitoring.A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature.Clinical management of rivaroxaban-treated patients.Investigational anticoagulants for hematological conditions: a new generation of therapies.Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis.Clinical relevance of β₂-glycoprotein-I plasma levels in antiphospholipid syndrome (APS).Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies.Antiphospholipid syndrome and the heart: a case series and literature review.Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants.Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort.Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome.Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant.Dosing of clopidogrel and aspirin in acute coronary syndromes.PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation.
P50
Q27014135-2C9BE1DB-895D-4B4F-84B3-EC0A0BB59F8FQ28218634-10999FB5-E093-4DA6-8C20-E1D735380777Q28547424-ECEB45FD-D2A1-47F6-8F12-CA82E0FC946EQ33269104-DF023DF8-491C-4302-9FE7-64B087368036Q33391969-49D89346-A342-4253-AE33-8BA4AB3949F8Q33392850-32C22B94-0B03-4C73-BFBD-BB5410209E81Q33425705-71EDABB0-1600-425C-923E-8BB526E8C25AQ33986110-9B234FEF-CA15-49DB-8415-F80EF3829700Q34082896-07A53DAB-C2EF-4373-BA19-37996214E090Q34145656-D342457C-1870-4B9A-A145-661B727A2852Q34150640-498536E7-9BF8-4327-9B8E-AB22F96B2FF3Q34283606-33CA8593-B0E9-45F3-AB7F-3BE44F8C4FD7Q34323100-07BD581A-D861-43A7-8D9F-C36EEC755AAFQ34576728-072B2585-6A9E-4AE9-A24C-25AB8D975E3DQ34949493-22F76E22-07A8-47F1-A336-6A06CDFA9C99Q36283533-41222006-FA8E-4E8A-8318-F617781C3135Q36731865-9B8F4DBD-A0D7-414E-8638-4EE7B5E40EB9Q37065161-E2A71C33-B5DA-41D5-A8DE-0AA6C005106FQ37286644-C2C66F76-8703-4414-9C31-56074989994CQ37554153-8E4A1504-7277-4631-9191-628ECEE6E86AQ37832035-AED5ADCD-1379-4AE2-9563-9CD1E593B07BQ37842673-2926F13E-2324-41A9-A887-FEED1D551882Q37880656-F33706E3-2578-4761-99C2-7BAF822D2233Q37991555-A8821569-92E2-43B6-B54B-636A83B362CFQ38065593-9239BFC1-E9D9-41F0-8D8A-17F5EC9F1DEAQ38075995-8B5F6117-8E5C-45E6-BCB4-4DC9223CEBC8Q38081946-31BC95FC-19D5-4338-8F83-7B4C12158A3FQ38123237-66C5C03A-4537-439D-882E-8D797312404AQ38159868-4E2DB766-5E06-4D75-8710-EC7E6A6C8CC8Q38209471-38079B46-FB9E-4D32-801F-D3BB6BC5590EQ38280730-C6B19312-976F-4F6A-8B46-7A72F3F4F4A9Q38280840-67081322-412E-4C84-869B-6FA818872D81Q38345740-AC3972A5-B497-4D25-8FEC-3333EAAF4D35Q38389058-CF4E0C22-9115-4F56-A9D8-F5CE3A86D05CQ41036908-A08AF948-B6B3-4F37-940D-1333B020FF95Q41619784-37B6B939-CFD5-4CB9-AD87-A7634E6DF826Q41747738-7121ABA3-D06A-4FE2-A8BC-B6A2F49D0E97Q42778526-486746AD-9264-4430-98AB-1525EA693F10Q43604229-48D49E88-DC10-4347-A087-0A6FFB5DFB60Q43796154-EFBB8826-EC81-4360-968A-F1119C1C10F3
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vittorio Pengo
@ast
Vittorio Pengo
@en
Vittorio Pengo
@es
Vittorio Pengo
@nl
Vittorio Pengo
@sl
type
label
Vittorio Pengo
@ast
Vittorio Pengo
@en
Vittorio Pengo
@es
Vittorio Pengo
@nl
Vittorio Pengo
@sl
prefLabel
Vittorio Pengo
@ast
Vittorio Pengo
@en
Vittorio Pengo
@es
Vittorio Pengo
@nl
Vittorio Pengo
@sl
P106
P1153
7005605212
P21
P31
P496
0000-0003-2064-6071